Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent E Wallner

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 2, 2009
Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
Urology|February 24, 2009
Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMBNathan Bittner, Gregory S Merrick, Hugo Andreini, et al.
International Journal of Radiation Oncology, Biology, Physics|July 2, 2005
Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidityZachariah A Allen, Gregory S Merrick, Wayne M Butler, et al.
Urologic Nursing|August 31, 2006
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancerMark A Moyad, Gregory S Merrick, Wayne M Butler, et al.
Brachytherapy|April 17, 2007
A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapyDaniel R Reed, Kent E Wallner, Gregory S Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapyL Christine Fang, Gregory S Merrick, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2009
Erectile function durability following permanent prostate brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
American Journal of Clinical Oncology|December 9, 2008
Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancerGregory S Merrick, Kent E Wallner, Robert W Galbreath, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2005
Erectile function after prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2002
The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunctionGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
International Journal of Radiation Oncology, Biology, Physics|January 2, 2009
Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
Urology|February 24, 2009
Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMBNathan Bittner, Gregory S Merrick, Hugo Andreini, et al.
International Journal of Radiation Oncology, Biology, Physics|July 2, 2005
Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidityZachariah A Allen, Gregory S Merrick, Wayne M Butler, et al.
Urologic Nursing|August 31, 2006
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancerMark A Moyad, Gregory S Merrick, Wayne M Butler, et al.
Brachytherapy|April 17, 2007
A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapyDaniel R Reed, Kent E Wallner, Gregory S Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapyL Christine Fang, Gregory S Merrick, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2009
Erectile function durability following permanent prostate brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
American Journal of Clinical Oncology|December 9, 2008
Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancerGregory S Merrick, Kent E Wallner, Robert W Galbreath, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2005
Erectile function after prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
International Journal of Radiation Oncology, Biology, Physics|November 7, 2002
The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunctionGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Pageof 12